Search Within

David H Ilson

  1. "Computational Oncology Service"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (13)
Groups
  1. Computational Oncology Service (30)
  2. Department of Medicine (30)
  3. Epidemiology and Biostatistics (30)
  4. GSK Faculty (30)
  5. Gastrointestinal Oncology Service (30)
  6. Hematologic Malignancies, Division of (30)

More Groups

People
  1. Geoffrey Ku (30)
  2. Nikolaus Schultz (30)
  3. Yelena Janjigian (30)
  4. David Solit (21)
  5. Jaclyn Hechtman (19)
  6. David Kelsen (18)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (4)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Clinical Cancer Research (4)
  3. Annals of Oncology (2)
  4. Cancer Discovery (2)
  5. JAMA Network Open (2)
  6. Annals of Surgery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. American Association for Cancer Research (6)
  3. Oxford University Press (4)
  4. American Medical Association (2)
  5. Elsevier Science, Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer
    Journal Article

    Won, E.; Basunia, A.; Chatila, W. K.; Hechtman, J. F.; Chou, J. F.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
    Journal Article

    Mondaca, S.; Margolis, M.; Sanchez-Vega, F.; Jonsson, P.; Riches, J. C.; Ku, G. Y.; Hechtman, J. F.; Tuvy, Y.; Berger, M. F.; Shah, M. A.; more...
    Gastric Cancer (2019)

    Fulltext@MSK | Save
  • EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer
    Journal Article

    Sanchez-Vega, F.; Hechtman, J. F.; Castel, P.; Ku, G. Y.; Tuvy, Y.; Won, H.; Fong, C. J.; Bouvier, N.; Nanjangud, G. J.; Soong, J.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Detection of germline homologous recombination deficiency (HRD) in patients with metastatic esophagogastric (EG) cancer using clinical next generation sequencing (NGS)
    Meeting Abstract

    Janjigian, Y. Y.; Jonsson, P.; Kemel, Y.; Joseph, V.; Tuvy, Y.; Shameer, Z.; Ravichandran, V.; Zhang, L. Y.; Mandelker, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden (TMB) and immune- related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC)
    Meeting Abstract

    Greally, M.; Chatila, W. K.; Margolis, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Ladanyi, M.; Kelsen, D. P.; Ilson, D. H.; Berger, M. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genetic predictors of response to systemic therapy in esophagogastric cancer
    Journal Article

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Chatila, W. K.; Hechtman, J. F.; Ku, G. Y.; Riches, J. C.; Tuvy, Y.; Kundra, R.; Bouvier, N.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients
    Meeting Abstract

    Ku, G. Y.; Sanchez-Vega, F.; Chatila, W.; Margolis, M.; Fein, C.; Ilson, D. H.; Hechtman, J. F.; Tuvy, Y.; Bouvier, N.; Kundra, R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Tuvy, Y.; Bouvier, N.; Riches, J. C.; Margolis, M.; Millang, B. M.; Scott, S. N.; Kundra, R.; Castel, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Tuvy, Y.; Bouvier, N.; Riches, J.; Kundra, R.; Ku, G.; Hechtman, J. F.; Kelsen, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Genomic profiling of esophagogastric (EG) tumors in clinical practice
    Meeting Abstract

    Riches, J. C.; Schultz, N.; Ku, G. Y.; Imtiaz, T.; Kelsen, D. P.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; Ladanyi, M.; Arcila, M. E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save